[1]倪雅倩,侯艳红,吴 方,等.他拉唑帕利联合恩扎卢胺治疗HRR基因突变转移性去势抵抗性前列腺癌的成本-效用分析[J].卫生经济研究,2026,43(09):43-48.
　NI Yaqian,HOU Yanhong,WU Fang,et al.Cost-Utility Analysis of Talazoparib Combined with Enzalutamide for HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer[J].Journal Press of Health Economics Research,2026,43(09):43-48.
点击复制

他拉唑帕利联合恩扎卢胺治疗HRR基因突变转移性去势抵抗性前列腺癌的成本-效用分析

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
43
期数:
2026年09期
页码:
43-48
栏目:
经济学评价
出版日期:
2026-09-02

文章信息/Info

Title:
Cost-Utility Analysis of Talazoparib Combined with Enzalutamide for HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer
作者:
倪雅倩1; 侯艳红1; 吴 方1; 陈伟伟1
1.中国药科大学国际医药商学院，江苏 南京 211198
Author(s):
NI Yaqian;  HOU Yanhong;  WU Fang;  CHEN Weiwei
School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing Jiangsu 211198, China
关键词:
他拉唑帕利; 恩扎卢胺; HRR基因突变; 转移性去势抵抗性前列腺癌; 成本-效用分析
Keywords:
talazoparib;  enzalutamide;  HRR gene mutation;  metastatic castration-resistant prostate cancer;  cost-utility analysis
分类号:
R95
文献标志码:
A
摘要:
目的：评价他拉唑帕利联合恩扎卢胺治疗同源重组修复（HRR）基因突变转移性去势抵抗性前列腺癌的成本-效用。方法：基于TALAPRO-2 Ⅲ期临床试验，构建分区生存模型，系统评估他拉唑帕利联合恩扎卢胺治疗HRR基因突变型转移性去势抵抗性前列腺癌的经济性；模型设置周期为1个月，模拟时限为10年；以质量调整生命年作为核心健康产出指标，计算联合治疗与单独用药的增量成本-效果比；采用敏感性分析对模型结果进行稳健性检验，确保评价结论的可靠性。结果：基础分析结果显示，当以我国2024年人均GDP的3倍为意愿支付阈值时，与恩扎卢胺单独用药方案相比，联合治疗方案不具经济性。结论：采取有效措施，包括优化定价策略、创新支付方式、优化临床路径、拓宽支付渠道等，提高创新药物的可及性，最终减轻患者的经济压力。
Abstract:
Objective To evaluate the cost-utility of talazoparib combined with enzalutamide in the treatment of HRR gene-mutated metastatic castration-resistant prostate cancer(mCRPC). Methods Based on the TALAPRO-2 Phase III clinical trial, a partitioned survival model was constructed to systematically assess the economic value of talazoparib combined with enzalutamide versus enzalutamide monotherapy. The model cycle was set at 1 month with a simulation horizon of 10 years. Quality-adjusted l ife years(QALYs) were used as the core health outcome measure, and the incremental cost-effectiveness ratio(ICER) was calculated. Sensitivity analyses were performed to test the robustness of the model results. Results The base-case analysis showed that, using three times China's 2024 per capita GDP as the willingness-to-pay threshold, the combination therapy was not cost-effective compared to enzalutamide monotherapy. Conclusion Further effective measures should be taken, including optimizing pricing strategies, exploring innovative payment methods, optimizing clinical pathways, and broadening payment channels to improve the accessibility of innovative drugs and ultimately reduce the financial burden on patients.

参考文献/References:

[1] Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. Ca: a Cancer Journal For Clinicians, 2024, 74(03): 229-263.
[2] Scott R. J, Mehta A, Macedo G S. Genetic testing for homologous recombination repair(HRR) in metastatic castration-resistant prostate cancer(mCRPC): challenges and solutions[J]. Oncotarget, 2021, 12(16): 1600-1614.
[3] Olmos D, Lorente D, Alameda D, et al.Treatment patterns and outcomes in metastatic castration-resistant prostate cancer patients with and without somatic or germline alterations in homologous recombination repair genes[J]. Annals of Oncology: Official Journal of the European Society for Medical Oncology, 2024, 35(05): 458-472.
[4] Fizazi K, Azad A, Matsubara N, et al. Talazoparib plus enzalutamide in men with HRR-deficient metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial[J]. Lancet (London, England), 2025, 406(10502): 461-474.
[5] 中国临床肿瘤学会.中国临床肿瘤学会（CSCO）前列腺癌诊疗指南2023[M].北京：人民卫生出版社，2023：114-115.
[6] 刘国恩.中国药物经济学评价指南2020[M].北京：中国市场出版社，2020：27-46.
[7] Zhu J, Li Z, Ding Y,et al. Cost-effectiveness of talazoparib plus enzalutamide as first-line therapy in metastatic castration-resistant prostate cancer[J]. Therapeutic Advances in Medical Oncology, 2025, 17: 17588359251367329.
[8] 申怡珂，龚瑞雪，郗有丽，等.阿比特龙一线治疗转移性去势抵抗性前列腺癌的成本-效用分析[J].中国医院用药评价与分析，2023，23（11）：1363-1368.
[9] Wu Y, Dong Z, Wang J, et al. Neratinib plus capecitabine versus lapatinib plus capecitabine as the third-line therapy for HER2-positive metastatic breast cancer in China: a cost-effectiveness analysis[J]. BMJ Open, 2022, 12(11): e065299.
[10] 武亚楠，吴方，侯艳红.德曲妥珠单抗对比恩美曲妥珠单抗二线治疗HER2阳性转移性乳腺癌的成本-效用分析[J].中国药房，2024，35（02）：204-209.
[11] 杨雷，王凤玲，黄玲，等.恩扎卢胺治疗转移性前列腺癌的成本-效果分析[J].药物流行病学杂志，2024，33（03）：269-276.
[12] Liu M, Qu S, Liu Y, et al. Comparative clinical effects and cost-effectiveness of maximum androgen blockade, docetaxel with androgen deprivation therapy and ADT alone for the treatment of mHSPC in China[J]. Journal of Comparative Effectiveness Research, 2019, 8(11): 865-877.
[13] Lu S, Yu Y, Fu S, et al. Cost-effectiveness of ALK testing and first-line crizotinib therapy for non-small-cell lung cancer in China[J]. PloS One, 2018, 13(10): e0205827.
[14] Shi G, Park S H, Ren H, et al. Cost analysis for different sequential treatment regimens for metastatic renal cell carcinoma in China[J]. Journal of Medical Economics, 2018, 21(12): 1150-1158.
[15] Barqawi Y K, Borrego M E, Roberts M H, et al. Cost-effectiveness model of abiraterone plus prednisone, cabazitaxel plus prednisone and enzalutamide for visceral metastatic castration resistant prostate cancer therapy after docetaxel therapy resistance[J]. Journal of Medical Economics, 2019, 22(11): 1202-1209.
[16] Zhang P F, Xie D, Li Q. Cost-effectiveness analysis of cabazitaxel for metastatic castration resistant prostate cancer after docetaxel and androgen-signaling-targeted inhibitor resistance[J]. BMC Cancer, 2021, 21(01): 35.
[17] Rui M, Wang Y, Wei Q, et al. HRR deficiency-guided use of talazoparib plus enzalutamide in patients with metastatic castration-resistant prostate cancer: a cost-effectiveness analysis[J]. Therapeutic Advances in Medical Oncology, 2025, 17, 1758835 9251356109.

更新日期/Last Update: 2026-09-02